A privately-held company developing
Proprietary drug transporter activating technology
For targeted and effective delivery of anticancer drugs
Molecular mimicry technology turning co-administered anti-cancer agents more efficacious, less toxic
Only a small fraction of the administered anti-cancer agent can make it into the tumor. The novel technology of DrugCendR turns the tumor microenvironment into a drug conduit, allowing efficient access of anti-cancer agents deep into the tumor. As a consequence, co-administered anti-cancer agents may become more tumor-targeted, leading to an improved efficacy, as well as an improved safety profile.
Current medications fail to sufficiently penetrate solid tumors.
Novel technology hijacks body’s own transport system to deliver anti-cancer drugs deep into the tumor.
Clinical-stage molecular mimicry agent validated has been validated in more than 150 publications.
Meet DrugCendR, Inc. at JP Morgan Healthcare Conference 2020 (January 12-16, San Francisco)